POLAR
Clinical Trial Program
A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
Phase III
Status
Follow-up
Tumour subtype:
HR+ breast cancer
Scenario
Adjuvant
COLLABORATORS
PRINCIPAL INVESTIGATORS
Elisabetta Munzone, MD (European Institute of Oncology, Milan)
Stefan Aebi, MD (Lucerne Cantonal Hospital)
